Although VASH2 was initially discovered as an angiogenesis inhibitor,9 later results indicated that VASH2 in fact promotes angiogenesis during injury repair.10 Our results also demonstrated that VASH2 promotes tumor angiogenesis in hepatocellular carcinoma (HCC) cells.11 Subsequently, VASH2 was discovered as a promoter of EMT in human malignancies.12 VASH2 is localized in both cytosol and nucleus and is abnormally expressed in various types of cancer cells. This evidence concerns the gene VASH2 and hepatocellular carcinoma.